"Dexmedetomidine is the drug that sedates and provides analgesia while leaving breathing almost untouched — a 'cooperative' sedation that mimics natural sleep. Its two shadows are bradycardia and hypotension, and a transient hypertension if you push the loading dose too fast."
Dr. Tanya Chawla's notes, triangulated with Miller's Anesthesia; Morgan & Mikhail's Clinical Anesthesiology; Stoelting's Pharmacology.A highly selective, complete α₂ agonist
Dexmedetomidine is the pharmacologically active d-enantiomer of medetomidine, an imidazole derivative. It is a highly selective and complete (full) agonist at the α₂-adrenergic receptor (a G-protein-coupled receptor). Its defining feature is selectivity:
It has five clinically useful properties — it is a hypnotic, sedative, anxiolytic, analgesic and sympatholytic agent. At higher doses / rapid boluses it can also stimulate α₁ receptors (contributing to transient vasoconstriction).
Where the α₂ receptors are — and what they do
| Subtype | Location | Effect |
|---|---|---|
| α₂A | CNS — locus coeruleus (brainstem) & presynaptic nerve terminals; dorsal horn | Sedation, analgesia, sympatholysis (the main therapeutic effects) |
| α₂B | Peripheral vascular smooth muscle; thalamus | Vasoconstriction → transient hypertension |
| α₂C | CNS — basal ganglia & hippocampus | Modulates cognition/analgesia; startle response |
Dexmedetomidine acts predominantly at α₂A > α₂B.
Highly protein-bound, hepatically cleared
| Parameter | Value |
|---|---|
| Routes | IV (usual), IM, oral, intranasal & nebulised (highly lipophilic → good mucosal absorption) |
| Protein binding | ~94% |
| Distribution t½ | ~6 min (rapid) |
| Elimination t½ | ~2–3 h |
| Metabolism | Hepatic — glucuronidation, methylation & hydroxylation (CYP2A6) → inactive metabolites |
| Excretion | Renal (metabolites) & biliary |
"Cooperative" sedation that mimics sleep
- Acts on α₂ receptors in the locus coeruleus → sedation resembling natural non-REM sleep: the patient is arousable and able to follow commands — ideal for procedures needing cooperation.
- Analgesia (supraspinal + spinal, via α₂A/α₂C in the dorsal horn) → opioid-sparing, reduces MAC and post-operative analgesic requirement; a useful adjuvant in central/peripheral neuraxial blockade.
- Reduces the incidence of emergence agitation & delirium — patients experience less delirium when sedated with dexmedetomidine.
- Possible neuroprotective role (modulation of pro-/anti-apoptotic proteins; ↓ glutamate).
- Does not significantly affect evoked potentials (amplitudes/latencies) → can be used during neurophysiological monitoring and wake-up tests.
| Plasma concentration | State |
|---|---|
| ~0.2–0.3 ng/mL | Arousable to touch (light, cooperative sedation) |
| ~1.9 ng/mL | Unarousable (deep sedation) |
The signature advantage — minimal respiratory depression
- Reduces minute ventilation but with no significant change in arterial oxygenation and a preserved response to CO₂.
- The hypercapnic arousal response is preserved — as in normal sleep — so apnoea is rare even at deep sedation levels.
- This makes it uniquely suited to sedating patients with an unsecured airway (awake fibreoptic intubation, MRI/procedural sedation, obstructive sleep apnoea).
A biphasic blood-pressure response
Early / bolus phase — transient hypertension + reflex bradycardia
A rapid loading dose stimulates peripheral post-synaptic α₂B (and α₁) receptors on vascular smooth muscle → vasoconstriction → ↑ BP, with a reflex bradycardia. Minimise by giving the load slowly or omitting it.
Later / central phase — hypotension & bradycardia
Central sympatholysis dominates → ↓ BP and ↓ HR. This is the sustained effect during infusion.
Side effects
- Hypotension (dose-dependent).
- Bradycardia — occasionally profound; caution with other negative chronotropes/heart block.
- AV block / AV dissociation.
- Transient hypertension with rapid loading.
Dose
Uses
- ICU sedation — cooperative, extubation-friendly sedation with little respiratory depression.
- Wake-up tests & neurophysiological monitoring (does not abolish evoked potentials).
- ↓ Emergence agitation & delirium.
- Premedication (anxiolysis, antisialagogue-like drying, blunts intubation/extubation pressor response).
- Reduces intra-operative anaesthetic requirement (MAC- and opioid-sparing); adjunct to maintenance of anaesthesia / TIVA.
- Awake fibreoptic intubation and awake craniotomy.
- Monitored anaesthesia care (MAC) — sedation for procedures under local/regional anaesthesia or for MRI.
- Regional adjuvant — prolongs neuraxial & peripheral nerve blocks; used in IVRA.
- Treatment of alcohol / drug withdrawal and post-operative shivering.
Key differences
| Dexmedetomidine | Clonidine | |
|---|---|---|
| α₂ : α₁ selectivity | ~1600 : 1 | ~200 : 1 |
| Agonist type | Full agonist | Partial agonist |
| Elimination t½ | ~2–3 h (titratable IV infusion) | ~6–12 h (longer) |
| Typical use | IV sedation/infusion, procedural sedation, block adjuvant | Oral/neuraxial premed & adjuvant, hypertension |
- Both are advantages: excellent sedation, potentiates opioid analgesia & benzodiazepine hypnosis, ↓ emergence delirium, mimics natural sleep with little respiratory depression, sympatholytic, and ↓ myocardial O₂ consumption (potentially protective).
High-yield one-liners
Q: α₂:α₁ selectivity of dexmedetomidine vs clonidine?
~1600:1 vs ~200:1 — dexmedetomidine is far more selective.
Q: Why so little respiratory depression?
It sedates via the locus coeruleus mimicking natural sleep; the hypercapnic arousal/CO₂ response is preserved.
Q: Explain the biphasic BP response.
Rapid bolus → peripheral α₂B/α₁ vasoconstriction → transient hypertension + reflex bradycardia; then central sympatholysis → hypotension & bradycardia.
Q: Which receptor subtype mediates sedation vs vasoconstriction?
α₂A (locus coeruleus) → sedation/analgesia/sympatholysis; α₂B (vascular smooth muscle) → vasoconstriction.
Q: Loading and maintenance dose for ICU sedation?
1 µg/kg over 10 min, then 0.2–0.7 µg/kg/h.
Q: Antagonist?
Atipamezole.
Q: Why is it ideal for awake fibreoptic intubation and awake craniotomy?
Cooperative, arousable sedation + analgesia + drying of secretions with minimal respiratory depression, and it does not abolish evoked potentials.
References
- Dr. Tanya Chawla. Dexmedetomidine — handwritten viva notes (primary source for this node).
- Gropper MA, Cohen NH, Eriksson LI, et al. (eds). Miller's Anesthesia. 9th ed. Elsevier; 2020.
- Butterworth JF, Mackey DC, Wasnick JD. Morgan & Mikhail's Clinical Anesthesiology. 7th ed. McGraw-Hill; 2022.
- Flood P, Rathmell JP, Urman RD. Stoelting's Pharmacology & Physiology in Anesthetic Practice. 6th ed. Wolters Kluwer; 2022.